126 related articles for article (PubMed ID: 8369109)
1. Vitamin E attenuates the development of haloperidol-induced dopaminergic hypersensitivity in rats: possible implications for tardive dyskinesia.
Gattaz WF; Emrich A; Behrens S
J Neural Transm Gen Sect; 1993; 92(2-3):197-201. PubMed ID: 8369109
[TBL] [Abstract][Full Text] [Related]
2. MK-771 antagonizes the enhanced response to apomorphine in rats treated chronically with haloperidol - implications for tardive dyskinesia.
Yarbrough GG; Faison EP; Antolik EK
Neurosci Lett; 1982 Dec; 34(3):321-3. PubMed ID: 6819493
[TBL] [Abstract][Full Text] [Related]
3. Protective effect of Curcumin, the active principle of turmeric (Curcuma longa) in haloperidol-induced orofacial dyskinesia and associated behavioural, biochemical and neurochemical changes in rat brain.
Bishnoi M; Chopra K; Kulkarni SK
Pharmacol Biochem Behav; 2008 Feb; 88(4):511-22. PubMed ID: 18022680
[TBL] [Abstract][Full Text] [Related]
4. Behavioural and biochemical alterations following haloperidol treatment and withdrawal: the animal model of tardive dyskinesia reexamined.
Rastogi SK; Rastogi RB; Singhal RL; Lapierre YD
Prog Neuropsychopharmacol Biol Psychiatry; 1983; 7(2-3):153-64. PubMed ID: 6137027
[TBL] [Abstract][Full Text] [Related]
5. The pathophysiology of tardive dyskinesia.
Klawans HL; Carvey P; Tanner CM; Goetz CG
J Clin Psychiatry; 1985 Apr; 46(4 Pt 2):38-41. PubMed ID: 2858479
[TBL] [Abstract][Full Text] [Related]
6. Molindone compared to haloperidol in a guinea-pig model of tardive dyskinesia.
Koller W; Curtin J; Fields J
Neuropharmacology; 1984 Oct; 23(10):1191-4. PubMed ID: 6240609
[TBL] [Abstract][Full Text] [Related]
7. Antagonism of dopamine supersensitivity by estrogen: neurochemical studies in an animal model of tardive dyskinesia.
Gordon JH; Diamond BI
Biol Psychiatry; 1981 Apr; 16(4):365-71. PubMed ID: 7194695
[TBL] [Abstract][Full Text] [Related]
8. Estrogen in experimental tardive dyskinesia.
Gordon JH; Borison RL; Diamond BI
Neurology; 1980 May; 30(5):551-4. PubMed ID: 7189262
[TBL] [Abstract][Full Text] [Related]
9. Amantadine reduces haloperidol-induced dopamine receptor hypersensitivity in the striatum.
Allen RM; Lane JD; Brauchi JT
Eur J Pharmacol; 1980 Jul; 65(2-3):313-5. PubMed ID: 7190503
[TBL] [Abstract][Full Text] [Related]
10. The effect of thioridazine on haloperidol induced behavioral hypersensitivity.
Klawans HL; Carvey PM; Nelson D; Tanner CM; Goetz CG
Life Sci; 1986 May; 38(19):1707-14. PubMed ID: 3702600
[TBL] [Abstract][Full Text] [Related]
11. Effect of D1 and D2 agonists in primates withdrawn from long-term treatment with haloperidol: the potential role of dopamine D1 receptors in dyskinesia.
Lublin H; Gerlach J; Peacock L
Clin Neuropharmacol; 1992 Dec; 15(6):448-58. PubMed ID: 1362136
[TBL] [Abstract][Full Text] [Related]
12. Further dopaminergic supersensitivity to dopamine agonists by subchronic administration of haloperidol in rats treated with colchicine.
Kamata K; Okuyama S; Hashimoto S; Aihara H; Kasuya Y
Jpn J Pharmacol; 1986 Oct; 42(2):329-32. PubMed ID: 3795627
[TBL] [Abstract][Full Text] [Related]
13. Effect of daily dose of chronic haloperidol and chronic apomorphine on behavioral hypersensitivity in the rat.
Kinon BJ; Merson D; Kane JM
Psychopharmacology (Berl); 1984; 84(3):347-51. PubMed ID: 6440181
[TBL] [Abstract][Full Text] [Related]
14. Behavioural subsensitivity induced by long-term administration of a low dose of haloperidol to rats.
Frussa-Filho R; Abílio VC; Bergamo M; Palermo-Neto J
J Pharm Pharmacol; 1997 Apr; 49(4):412-5. PubMed ID: 9232539
[TBL] [Abstract][Full Text] [Related]
15. Theophylline, adenosine receptor antagonist prevents behavioral, biochemical and neurochemical changes associated with an animal model of tardive dyskinesia.
Bishnoi M; Chopra K; Kulkarni SK
Pharmacol Rep; 2007; 59(2):181-91. PubMed ID: 17556796
[TBL] [Abstract][Full Text] [Related]
16. Effects of buspirone on dopaminergic supersensitivity.
Queiroz CM; Frussa-Filho R
Life Sci; 1997; 61(4):371-82. PubMed ID: 9244363
[TBL] [Abstract][Full Text] [Related]
17. The effect of lithium on an animal model of tardive dyskinesia.
Klawans HL; Weiner WJ; Nausieda PA
Prog Neuropsychopharmacol; 1977; 1(1-2):53-60. PubMed ID: 569341
[No Abstract] [Full Text] [Related]
18. MSH and MIF-I in animal models of tardive dyskinesia.
Davis KL; Kastin AJ; Beilstein BA; Vento AL
Pharmacol Biochem Behav; 1980 Jul; 13(1):37-40. PubMed ID: 6105677
[TBL] [Abstract][Full Text] [Related]
19. Possible antioxidant and neuroprotective mechanisms of FK506 in attenuating haloperidol-induced orofacial dyskinesia.
Singh A; Naidu PS; Kulkarni SK
Eur J Pharmacol; 2003 Sep; 477(2):87-94. PubMed ID: 14519411
[TBL] [Abstract][Full Text] [Related]
20. Dopaminergic supersensitivity: influence of dopamine agonists, cholinergics, anticholinergics, and drugs used for the treatment of tardive dyskinesia.
Christensen AV; Nielsen IM
Psychopharmacology (Berl); 1979 Apr; 62(2):111-6. PubMed ID: 111273
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
